BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19302530)

  • 1. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
    Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
    Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
    Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
    Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Cytokeratin CAM5.2 (BD) does not act as a substitute of the CK8/18 monoclonal antibody. Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma'. Histopathology 2009; 54; 607-613.
    Hsu JD; Yao CC; Yuan CC; Lai CR; Ting LT; Li YJ; Han CP
    Histopathology; 2010 May; 56(6):810; author reply 810-1. PubMed ID: 20546346
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
    Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
    Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
    Ostroumov E; Hunter CJ
    Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
    Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
    Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
    Naka T; Boltze C; Kuester D; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Am J Clin Pathol; 2004 Dec; 122(6):926-30. PubMed ID: 15539385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
    Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
    Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.
    Chen YS; Wang JT; Chang YF; Liu BY; Wang YP; Sun A; Chiang CP
    J Oral Pathol Med; 2004 Apr; 33(4):209-17. PubMed ID: 15061708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
    Sakai K; Hongo K; Tanaka Y; Nakayama J
    Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression of hepatocyte growth factor and its receptor c-Met correlates with high MIB-1 proliferative index in malignant fibrous histiocytoma.
    Yamamoto T; Marui T; Akisue T; Nakatani T; Fujita I; Matsumoto K; Hitora T; Kawamoto T; Nagira K; Kurosaka M
    Pathol Res Pract; 2004; 200(5):397-402. PubMed ID: 15239348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
    Osada S; Kanematsu M; Imai H; Goshima S
    Hepatogastroenterology; 2008; 55(82-83):544-9. PubMed ID: 18613405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of HGF and its receptor c-Met in renal cell carcinoma].
    Shi BB; Zhang XH; Wang HJ; Li HZ
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):356-8. PubMed ID: 15312347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors.
    Trovato M; Vitarelli E; Grosso M; Alesci S; Benvenga S; Trimarchi F; Barresi G
    Eur J Histochem; 2004; 48(3):291-7. PubMed ID: 15590419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
    Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
    Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.